Company Filing History:
Years Active: 1997-1999
Title: **Carl L. Illig: Innovator in Thrombin Inhibition**
Introduction
Carl L. Illig is an accomplished inventor based in Phoenixville, PA, known for his significant contributions in the field of pharmaceutical compounds, particularly in protease inhibitors. With a total of two patents to his name, Illig's work focuses on developing novel compounds that are poised to advance treatment options for various serious medical conditions.
Latest Patents
Among his latest patents, Illig has made strides in the creation of amidinohydrazones as protease inhibitors. These compounds, which include specific formulas and their derivatives, are designed to inhibit proteolytic enzymes such as thrombin. This invention also outlines methods for synthesizing these compounds, lending valuable insight for future pharmaceutical applications. Additionally, Illig's work on thrombin inhibitors presents new, innovative compounds that target arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases, further showcasing his expertise in therapeutic development.
Career Highlights
Carl L. Illig is affiliated with 3-Dimensional Pharmaceuticals, Inc., where he collaborates with a team dedicated to discovering and developing cutting-edge pharmaceutical solutions. His inventive achievements reflect a deep understanding of medicinal chemistry and a commitment to improving patient outcomes.
Collaborations
Illig works alongside notable coworkers such as Richard M. Soll and Tianbao Lu. Their collective expertise and innovative approaches foster an environment ripe for discovery, emphasizing teamwork and collaboration in the research and development of new therapeutic agents.
Conclusion
In summary, Carl L. Illig's contributions to the field of protease inhibitors and thrombin inhibitors represent a significant advancement in pharmaceutical innovation. His work, characterized by a dedication to research and collaboration, is paving the way for breakthroughs that could transform treatment regimens for various complex diseases.